Z 360

Drug Profile

Z 360

Alternative Names: Z-360

Latest Information Update: 21 Sep 2015

Price : $50

At a glance

  • Originator Zeria
  • Class Gastric antisecretories
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Discontinued Peptic ulcer

Most Recent Events

  • 21 Sep 2015 No recent reports on development identified - Phase-I/II for Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease) in United Kingdom (PO)
  • 26 Apr 2014 Phase-II clinical trials in Pancreatic cancer (metastatic disease; combination therapy) in Japan, South Korea & Taiwan (PO)
  • 31 Jul 2013 Zeria Pharmaceutical completes a phase I trial in Healthy volunteers in Japan (NCT01776463)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top